

Supplementary material

Temporal trends in cardiovascular risk factors, lifestyle, and secondary preventive medication for patients with myocardial infarction attending cardiac rehabilitation in Sweden 2006-2019: a registry-based cohort study

Table S1. Patient characteristics during hospitalization (continuous variables) by year. Data are presented as median values (q1, q3).

1

Year	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	p for trend
N	2502	3942	5223	4948	4720	5368	5976	6530	6432	6831	7121	7073	7269	7428	
Age (years)	63 (57, 69)	63 (57, 69)	63 (57, 69)	63 (57, 69)	63 (57, 69)	64 (57, 69)	64 (57, 69)	64 (57, 69)	64 (57, 69)	64 (57, 69)	65 (57, 70)	64 (57, 70)	65 (58, 70)	65 (58, 70)	<0.0001
N missing	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Systolic BP (mmHg)	150 (130, 170)	147 (130, 165)	145 (130, 165)	146 (130, 165)	147 (130, 165)	149 (130, 168)	150 (130, 170)	150 (130, 170)	150 (131, 170)	150 (132, 170)	150 (133, 170)	150 (132, 170)	150 (133, 170)	150 (130, 169)	<0.0001
N missing	293	406	479	456	308	7	18	36	48	51	44	2	3	4	
Diastolic BP (mmHg)	85 (74, 100)	85 (75, 98)	85 (75, 97)	85 (75, 97)	85 (75, 96)	85 (75, 98)	87 (76, 100)	88 (77, 100)	88 (78, 100)	89 (79, 100)	89 (78, 99)	89 (79, 100)	90 (79, 100)	89 (79, 100)	<0.0001
N missing	330	471	529	509	410	130	176	213	290	299	261	227	352	454	
Total cholesterol (mmol/L)	5.0 (4.3, 5.8)	5.0 (4.2, 5.8)	4.9 (4.2, 5.7)	5.0 (4.2, 5.8)	5.1 (4.3, 5.9)	5.1 (4.3, 6.0)	5.1 (4.3, 6.0)	5.1 (4.3, 6.0)	5.0 (4.2, 5.9)	5.0 (4.2, 5.8)	5.0 (4.2, 5.9)	5.0 (4.1, 5.8)	5.0 (4.1, 5.9)	4.9 (4.0, 5.7)	<0.0001
N missing	329	554	788	833	835	1108	1185	1280	1204	1088	947	835	686	727	
LDL-C (mmol/L)	3.0 (2.3, 3.7)	3.0 (2.3, 3.7)	3.0 (2.3, 3.7)	3.1 (2.3, 3.8)	3.2 (2.5, 3.9)	3.2 (2.5, 3.9)	3.2 (2.5, 4.0)	3.2 (2.4, 3.9)	3.1 (2.3, 3.9)	3.1 (2.3, 3.8)	3.1 (2.3, 3.9)	3.0 (2.2, 3.8)	3.0 (2.2, 3.8)	3.0 (2.2, 3.8)	<0.0001
N missing	471	844	1008	972	1001	1272	1420	1678	1395	1234	1028	927	629	663	
HDL-C (mmol/L)	1.2 (1.0, 1.4)	1.2 (1.0, 1.4)	1.1 (0.9, 1.4)	1.1 (0.9, 1.3)	1.1 (0.9, 1.3)	1.1 (0.9, 1.4)	1.1 (0.9, 1.4)	1.1 (1.0, 1.4)	1.1 (1.0, 1.4)	1.1 (0.9, 1.4)	1.1 (0.9, 1.4)	1.2 (1.0, 1.4)	1.2 (0.9, 1.4)	1.1 (0.9, 1.4)	0.003
N missing	455	821	898	886	941	1214	1330	1519	1374	1188	987	901	746	766	

2

Year	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	p for trend
N	2502	3942	5223	4948	4720	5368	5976	6530	6432	6831	7121	7073	7269	7428	
Triglycerides (mmol/L)	1.5 (1.1, 2.2)	1.5 (1.1, 2.1)	1.5 (1.1, 2.1)	1.5 (1.1, 2.1)	1.4 (1.1, 2.0)	1.4 (1.0, 2.0)	1.4 (1.0, 1.9)	1.4 (1.0, 1.9)	1.4 (1.0, 2.0)	1.4 (1.0, 2.0)	1.4 (1.0, 2.0)	1.4 (1.0, 2.0)	1.4 (1.0, 2.0)	1.4 (1.0, 2.0)	<0.0001
N missing	391	769	897	901	923	1170	1318	1599	1500	1601	1488	1460	1481	1472	
F-glucose (mmol/L)	6.7 (5.6, 8.4)	6.6 (5.7, 8.3)	6.7 (5.7, 8.4)	6.8 (5.7, 8.5)	6.7 (5.8, 8.3)	6.8 (5.8, 8.5)	6.7 (5.8, 8.4)	6.7 (5.9, 8.5)	6.8 (5.9, 8.5)	6.8 (5.9, 8.6)	6.9 (5.9, 8.7)	6.9 (5.9, 8.7)	6.9 (5.9, 8.6)	7.0 (6.0, 8.8)	<0.0001
N missing	213	332	452	363	324	727	1034	1147	1014	767	762	643	812	1011	
HbA1c (mmol/mol)*	N/A	N/A	N/A	N/A	N/A	59.0 (50.0, 71.0)	59.0 (48.0, 73.0)	58.0 (50.0, 73.0)	61.0 (50.0, 74.0)	60.0 (50.0, 77.0)	59.0 (48.0, 74.0)	56.0 (48.0, 69.0)	56.0 (48.0, 72.0)	57.0 (48.0, 69.0)	0.012
N missing	484	730	977	996	852	776	872	1059	949	1071	1113	980	973	1012	
BMI (kg/m ²)	26.7 (24.6, 29.4)	26.9 (24.7, 29.7)	26.9 (24.5, 29.7)	26.9 (24.5, 29.8)	27.0 (24.7, 29.9)	27.1 (24.7, 30.0)	27.2 (24.7, 30.1)	27.2 (24.7, 30.1)	27.2 (24.8, 30.1)	27.2 (24.7, 30.1)	27.4 (24.8, 30.5)	27.4 (24.9, 30.4)	27.5 (24.9, 30.5)	27.5 (24.9, 30.7)	<0.0001
N missing	793	955	898	861	862	316	263	167	183	166	205	169	207	234	

*Patients with diabetes only. BMI, body mass index; BP, blood pressure; F, fasting; HbA1c, hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; N, number; N/A, no data available; q1, lower quartile; q3, upper quartile.

Table S2. Patient characteristics during hospitalization (categorical variables) by year. Data are presented as numbers (N) and proportions (%). ³

Year	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	p for trend
N	2502	3942	5223	4948	4720	5368	5976	6530	6432	6831	7121	7073	7269	7428	
Male sex	73.5%	74.4%	73.1%	73.7%	74.1%	74.5%	74.6%	74.1%	76.2%	75.3%	74.5%	76.2%	75.1%	75.2%	<0.0001
N missing	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Current smoking	32.0%	32.6%	32.4%	32.1%	30.8%	30.4%	30.4%	30.1%	28.9%	28.5%	28.0%	27.6%	27.4%	26.5%	<0.0001
N missing	99	150	161	171	130	215	128	143	124	132	145	145	172	177	
Overweight/obese (BMI \geq 25 kg/m ²)	70.7%	71.5%	70.2%	69.8%	72.1%	71.6%	71.9%	72.1%	73.3%	72.0%	73.2%	74.1%	74.0%	74.1%	<0.0001
N missing	793	955	898	861	862	316	263	167	183	166	205	169	207	234	
Obese (BMI \geq 30 kg/m ²)	22.8%	23.8%	23.4%	23.9%	24.3%	25.4%	26.0%	25.9%	26.0%	26.4%	28.7%	27.9%	29.0%	29.5%	<0.0001
N missing	793	955	898	861	862	316	263	167	183	166	205	169	207	234	
Use of antihypertensive drugs*	47.5%	47.9%	49.1%	49.9%	48.0%	48.4%	49.2%	49.4%	49.2%	49.4%	49.8%	50.3%	48.9%	50.5%	<0.0001
N missing	6	13	9	24	15	41	26	33	31	23	84	85	92	99	
Use of lipid lowering drugs†	24.5%	25.0%	26.5%	28.8%	27.7%	28.4%	28.4%	28.8%	27.6%	27.9%	27.7%	28.0%	26.9%	28.6%	0.004
N missing	8	17	15	30	20	44	29	39	29	31	94	103	102	131	
Prior diabetes diagnosis	19.3%	18.5%	18.7%	20.1%	18.1%	18.8%	18.9%	20.3%	19.7%	20.5%	21.7%	21.1%	21.5%	22.6%	<0.0001
N missing	0	0	1	0	0	2	0	1	0	6	1	2	13	21	
Prior ASCVD diagnosis‡	23.3%	24.5%	23.8%	23.8%	22.8%	22.8%	26.5%	28.2%	26.5%	26.9%	27.4%	28.2%	27.2%	27.9%	<0.0001
N missing	0	0	0	0	0	2	0	0	0	0	0	0	0	0	

*ACE inhibitor, ARB, beta blocker, diuretics, and/or calcium channel blocker. †Statins and/or ezetimibe. ‡MI, PCI, CABG or stroke. ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index;

CABG, coronary artery bypass grafting; eGFR, estimated glomerular filtration rate; MI, myocardial infarction; PCI, percutaneous coronary intervention. †

Table S3. Type of MI, revascularization during hospitalization, and pharmacological treatment at discharge by year. Data are presented as numbers (N) and proportions (%).

Year	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	p for trend
N	2502	3942	5223	4948	4720	5368	5976	6530	6432	6831	7121	7073	7269	7428	
STEMI	39.3%	38.8%	36.4%	38.9%	39.7%	39.2%	37.6%	37.2%	38.9%	38.9%	38.6%	38.9%	40.4%	40.5%	<0.0001
N missing	0	1	2	69	52	48	55	5	0	0	0	0	0	0	
Revascularized* during hospitalization	65.1%	71.5%	71.1%	71.1%	76.4%	87.3%	82.2%	83.9%	86.0%	88.6%	88.5%	89.6%	90.6%	90.3%	<0.0001
N missing	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Discharge medication															
Statin	90.4%	93.5%	94.7%	95.7%	96.7%	96.8%	97.1%	96.8%	97.3%	97.7%	97.5%	97.3%	96.9%	97.0%	<0.0001
N missing	1	2	4	1	1	2	1	4	5	2	0	2	2	8	
Ezetimibe	1.3%	1.5%	2.0%	2.0%	1.5%	1.6%	1.5%	1.5%	1.6%	1.5%	2.4%	3.1%	4.2%	5.1%	<0.0001
N missing	3	7	16	7	4	4	3	8	7	2	1	0	798	4	
ACE-inhibitor/ARB	64.3%	67.1%	72.4%	75.6%	78.9%	82.5%	82.8%	84.0%	83.9%	85.1%	85.1%	85.8%	85.3%	84.7%	<0.0001
N missing	3	6	6	2	3	9	3	5	6	3	3	1	2	4	
Beta blocker	92.2%	90.6%	92.3%	93.1%	92.8%	93.2%	92.1%	91.9%	90.9%	90.2%	90.3%	89.7%	88.2%	81.5%	<0.0001
N missing	2	3	7	0	0	3	2	0	3	2	1	1	2	4	
Acetylsalicylic acid	94.0%	96.2%	95.9%	96.2%	96.6%	96.9%	97.6%	97.2%	96.3%	96.2%	95.9%	96.2%	95.9%	95.3%	0.114
N missing	1	1	3	0	0	2	2	1	4	1	9	3	5	5	
P2Y ₁₂ -receptor antagonist	79.3%	84.0%	84.5%	86.0%	89.2%	87.4%	82.8%	85.3%	89.9%	90.5%	91.2%	90.9%	90.7%	91.0%	<0.0001
N missing	0	0	0	0	0	0	0	0	0	0	0	0	1	1	

Year	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	⁶ p for trend
N	2502	3942	5223	4948	4720	5368	5976	6530	6432	6831	7121	7073	7269	7428	
DAPT/DAT/TAT	78.1%	83.9%	84.2%	85.8%	88.6%	87.5%	83.3%	85.3%	89.8%	90.7%	91.2%	91.2%	91.1%	91.5%	<0.0001
N missing	1	1	3	0	0	2	2	1	4	1	9	3	5	5	

*Percutaneous coronary intervention or coronary artery bypass grafting. ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; DAPT, dual antiplatelet therapy; DAT, dual antithrombotic therapy; N, number; N/A, no data available; STEMI, ST-elevation myocardial infarction; TAT, triple antithrombotic therapy.

Table S4. Median (q1, q3) values for selected continuous variables at the one-year follow-up visit.

7

Year	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	p for trend
N	2502	3942	5223	4948	4720	5368	5976	6530	6432	6831	7121	7073	7269	7428	
Systolic BP (mmHg)	130 (120, 145)	130 (120, 140)	130 (120, 140)	130 (120, 140)	130 (120, 140)	130 (120, 140)	130 (120, 140)	130 (120, 140)	130 (120, 140)	130 (120, 140)	130 (120, 138)	130 (120, 138)	130 (120, 137)	128 (120, 135)	<0.0001
N missing	869	1308	1351	996	711	945	999	675	381	339	262	196	234	219	
Diastolic BP (mmHg)	80 (70, 82)	78 (70, 80)	80 (70, 80)	76 (70, 80)	80 (70, 80)	80 (70, 80)	80 (70, 84)	80 (70, 82)	79 (70, 82)	78 (70, 80)	77 (70, 80)	77 (70, 81)	76 (70, 81)	76 (70, 80)	<0.0001
N missing	871	1314	1364	999	715	947	1008	689	392	344	267	201	238	226	
Total cholesterol (mmol/L)	4.2 (3.6, 4.8)	4.1 (3.6, 4.7)	4.1 (3.6, 4.6)	4.2 (3.7, 4.7)	4.1 (3.6, 4.7)	4.2 (3.6, 4.8)	4.1 (3.6, 4.7)	4.0 (3.5, 4.6)	3.8 (3.3, 4.4)	3.7 (3.2, 4.3)	3.6 (3.2, 4.2)	3.5 (3.1, 4.1)	3.4 (3.0, 4.0)	3.3 (2.9, 3.8)	<0.0001
N missing	690	1383	1819	1664	1117	1152	1162	759	410	434	407	345	381	370	
LDL-C (mmol/L)	2.1 (1.7, 2.6)	2.2 (1.8, 2.6)	2.2 (1.7, 2.6)	2.3 (1.9, 2.7)	2.2 (1.8, 2.7)	2.2 (1.8, 2.7)	2.2 (1.8, 2.7)	2.1 (1.7, 2.5)	1.9 (1.6, 2.4)	1.8 (1.5, 2.3)	1.8 (1.4, 2.2)	1.7 (1.4, 2.1)	1.7 (1.4, 2.1)	1.6 (1.3, 1.9)	<0.0001
N missing	729	1443	1891	1745	1247	1238	1310	837	439	419	338	244	255	224	
HDL-C (mmol/L)	1.3 (1.1, 1.5)	1.2 (1.0, 1.4)	1.2 (1.0, 1.4)	1.2 (1.0, 1.4)	1.2 (1.0, 1.4)	1.2 (1.0, 1.5)	1.2 (1.0, 1.5)	1.2 (1.0, 1.5)	1.2 (1.0, 1.5)	1.2 (1.0, 1.5)	1.2 (1.0, 1.5)	1.2 (1.0, 1.5)	1.2 (1.0, 1.4)	1.2 (1.0, 1.4)	0.552
N missing	714	1423	1860	1720	1180	1217	1253	850	481	627	679	644	667	641	
Triglycerides (mmol/L)	1.4 (1.0, 1.9)	1.3 (1.0, 1.9)	1.3 (1.0, 1.9)	1.4 (1.0, 1.9)	1.3 (1.0, 1.8)	1.3 (1.0, 1.8)	1.3 (1.0, 1.8)	1.3 (1.0, 1.8)	1.2 (0.9, 1.7)	1.2 (0.9, 1.7)	1.2 (0.9, 1.6)	1.2 (0.9, 1.7)	1.2 (0.9, 1.6)	1.1 (0.8, 1.6)	<0.0001
N missing	720	1415	1869	1701	1204	1192	1286	907	727	966	1153	1139	1259	1175	

8

Year	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	p for trend
N	2502	3942	5223	4948	4720	5368	5976	6530	6432	6831	7121	7073	7269	7428	
F-glucose (mmol/L)	5.7 (5.2, 6.5)	5.7 (5.2, 6.4)	5.7 (5.2, 6.6)	5.7 (5.2, 6.5)	5.7 (5.3, 6.5)	5.8 (5.3, 6.6)	5.8 (5.3, 6.6)	5.9 (5.4, 6.8)	5.9 (5.4, 6.7)	6.0 (5.5, 6.7)	6.0 (5.5, 6.8)	6.0 (5.5, 6.8)	6.0 (5.5, 6.7)	6.0 (5.5, 6.8)	<0.0001
N missing	893	1391	1820	1639	1374	1777	2128	1923	1953	2332	2376	2598	2830	3006	
HbA1c (mmol/mol)*	56.0 (49.0, 68.0)	56.5 (49.0, 68.0)	56.0 (48.0, 66.0)	55.0 (48.0, 67.0)	55.0 (49.0, 69.0)	56.0 (49.0, 68.0)	58.0 (50.0, 70.0)	57.0 (48.0, 69.0)	54.0 (47.0, 67.0)	55.0 (46.0, 66.0)	55.0 (47.0, 66.0)	54.0 (46.0, 66.0)	53.0 (46.0, 63.0)	52.0 (46.0, 64.0)	<0.0001
N missing	165	215	242	274	267	372	407	496	595	676	735	755	801	868	
BMI (kg/m ²)	26.8 (24.7, 29.7)	27.1 (24.7, 30.0)	27.2 (24.8, 30.1)	27.1 (24.7, 30.0)	27.2 (24.8, 30.2)	27.2 (24.8, 30.2)	27.4 (24.8, 30.4)	27.2 (24.8, 30.3)	27.2 (24.8, 30.2)	27.3 (24.6, 30.3)	27.4 (24.7, 30.6)	27.4 (24.8, 30.6)	27.4 (24.8, 30.5)	27.4 (24.8, 30.6)	0.0007
N missing	1203	1694	1899	1751	1462	1292	1583	1442	1367	1589	1782	1874	2396	2630	
Waist circumference (cm)	99 (92, 106)	100 (93, 107)	100 (92, 107)	100 (93, 107)	100 (93, 108)	100 (93, 108)	100 (93, 108)	100 (93, 108)	101 (93, 109)	101 (93, 109)	101 (93, 110)	101 (94, 110)	101 (93, 110)	101 (94, 109)	<0.0001
N missing	1306	1799	2111	1771	1409	1822	2079	2246	2138	2551	2984	3301	3789	4403	
Physical activity (days)**	4 (1, 7)	4 (1, 7)	4 (1, 7)	4 (1, 7)	3 (1, 7)	4 (1, 7)	3 (1, 6)	3 (1, 7)	3 (1, 7)	4 (1, 7)	3 (1, 7)	3 (1, 6)	3 (1, 6)	3 (1, 6)	<0.0001
N missing	140	237	551	377	24	112	59	55	40	37	56	35	59	68	

*Patients with diabetes only. ** Days during the last week of physical activity (at least 30 minutes per day). BMI, body mass index; BP, blood pressure; F, fasting; HbA1c, hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; N, number; N/A, no data available; q1, lower quartile; q3, upper quartile.

Table S5. Mean (+/-SD) delta values between hospitalization and one-year follow-up for selected continuous variables.

9

Year	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	p for trend
Systolic BP (mmHg)	-25.2 (25.8)	-25.2 (26.0)	-24.5 (26.0)	-25.4 (25.8)	-25.8 (25.9)	-26.5 (25.7)	-26.5 (25.5)	-26.9 (26.0)	-28.5 (26.4)	-28.4 (25.3)	-29.9 (25.2)	-29.5 (25.5)	-29.9 (25.1)	-30.2 (24.9)	<0.0001
Diastolic BP (mmHg)	-16.6 (13.5)	-16.7 (14.7)	-16.1 (14.6)	-17.2 (14.5)	-16.2 (14.1)	-16.2 (14.2)	-16.0 (14.6)	-16.7 (14.6)	-17.2 (14.8)	-17.5 (14.2)	-18.1 (14.4)	-17.9 (14.3)	-18.4 (14.0)	-20.1 (14.3)	<0.0001
LDL-C (mmol/L)	-0.83 (1.11)	-0.75 (1.05)	-0.83 (1.10)	-0.78 (1.12)	-0.89 (1.11)	-0.91 (1.13)	-0.93 (1.17)	-1.02 (1.21)	-1.10 (1.16)	-1.13 (1.17)	-1.23 (1.19)	-1.24 (1.18)	-1.26 (1.21)	-1.29 (1.20)	<0.0001
F-glucose (mmol/L)	-1.59 (3.33)	-1.40 (3.02)	-1.46 (3.08)	-1.52 (3.16)	-1.46 (3.17)	-1.47 (2.85)	-1.36 (3.02)	-1.30 (3.10)	-1.40 (3.17)	-1.37 (3.08)	-1.42 (3.11)	-1.37 (2.87)	-1.45 (3.11)	-1.62 (3.39)	0.670
HbA1c (mmol/mol) *	N/A	N/A	N/A	N/A	N/A	-1.5 (- 9.0, 5.0)	-1.0 (- 11.0, 5.0)	-2.0 (- 10.0, 4.0)	-1.0 (- 10.0, 3.0)	0.0 (-8.0, 6.0)	-1.0 (- 9.0, 5.0)	0.0 (-7.0, 6.0)	0.0 (-7.0, 5.0)	-1.0 (-9.0, 4.0)	0.297
BMI (kg/m ²)	0.24 (1.80)	0.17 (1.91)	0.30 (1.80)	0.23 (1.88)	0.25 (1.86)	0.23 (1.91)	0.21 (1.91)	0.09 (1.91)	0.06 (1.88)	0.04 (2.06)	-0.03 (2.00)	-0.01 (1.97)	-0.11 (2.09)	-0.15 (2.11)	<0.0001

*Patients with diabetes only. BMI, body mass index; BP, blood pressure; CCU, coronary care unit; F, fasting; HbA1c, hemoglobin A1c; LDL-C, low-density lipoprotein cholesterol; N, number; N/A, no data available; SD, standard deviation.

Table S6. Patient demographics for the EUROASPIRE surveys III, IV and V (1-3).

10

Survey	Years conducted	Number of patients	% men	Number of participating centres	Number of participating countries	Median (IQR) time (years) after index event
III	2006-2007	8966	73%	76	22	1.2 (1.0-1.8)
IV	2011-2012	7998	76%	78	24	1.4 (1.0-1.9)
V	2016-2017	8261	74%	131	27	1.1 (0.8-1.6)

IQR, inter quartile range.




Figure S1. Lifestyle factors at one-year in SWEDHEART (left panel) and EUROASPIRE (right panel) where comparable data in the two cohorts was available (1-3). ^aBody mass index ≥ 25 kg/m²; ^bwaist circumference ≥ 102 cm for men and ≥ 88 cm for women.




Figure S2. Proportion of patients at one-year follow-up for each year 2006-2019 in SWEDEHEART treated with lipid lowering therapy (statins or ezetimibe), ACEi or ARB, beta blockers or antiplatelet therapy (ASA or P2Y₁₂-receptor antagonists). Corresponding data from the EUROASPIRE III-V surveys shown on the right panel of the figure (1-3). In EUROASPIRE lipid lowering drugs included statins, ezetimibe, fibrates, bile acid sequestrants and nicotinic acid.

ACEi, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers; ASA, acetylsalicylic acid.

References

1

1. Kotseva K, De Backer G, De Bacquer D, Ryden L, Hoes A, Grobbee D, et al. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. *Eur J Prev Cardiol.* 2019;26(8):824-35.
2. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K, Keil U, et al. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. *Eur J Cardiovasc Prev Rehabil.* 2009;16(2):121-37.
3. Kotseva K, Wood D, De Bacquer D, De Backer G, Ryden L, Jennings C, et al. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. *Eur J Prev Cardiol.* 2016;23(6):636-48.